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The involvement of histamine H3 receptors (H3Rs) in memory is well known, and the
potential of H3R antagonists in therapeutic management of neuropsychiatric diseases,
e.g., Alzheimer disease (AD) is well established. Therefore, the effects of histamine H3
receptor (H3R) antagonist E159 (2.5–10 mg/kg, i.p.) in adult male rats on dizocilpine
(DIZ)-induced memory deficits were studied in passive avoidance paradigm (PAP)
and in novel object recognition (NOR) using pitolisant (PIT) and donepezil (DOZ) as
standard drugs. Upon acute systemic pretreatment of E159 at three different doses,
namely 2.5, 5, and 10 mg/kg, i.p., 2.5 and 5 but not 10 mg/kg of E159 counteracted
the DIZ (0.1 mg)-induced memory deficits, and this E159 (2.5 mg)-elicited memory-
improving effects in DIZ-induced amnesic model were moderately abrogated after acute
systemic administration of scopolamine (SCO), H2R antagonist zolantidine (ZOL), but
not with H1R antagonist pyrilamine to the animals. Moreover, the observed memory-
enhancing effects of E159 (2.5 mg/kg, i.p.) were strongly abrogated when animals were
administered with a combination of SCO and ZOL. Furthermore, the E159 (2.5 mg)-
provided significant memory-improving effect of in DIZ-induced short-term memory
(STM) impairment in NOR was comparable to the DOZ-provided memory-enhancing
effect, and was abolished when animals were injected with the CNS-penetrant histamine
H3R agonist R-(α)-methylhistamine (RAMH). However, E159 at a dose of 2.5 mg/kg
failed to exhibit procognitive effect on DIZ-induced long-term memory (LTM) in NOR.
Furthermore, the results observed revealed that E159 (2.5 mg/kg) did not alter
anxiety levels and locomotor activity of animals naive to elevated-plus maze (EPM),
demonstrating that improved performances with E159 (2.5 mg/kg) in PAP or NOR are
unrelated to changes in emotional responding or in spontaneous locomotor activity.
These results provide evidence for the potential of drugs targeting H3Rs for the
treatment of neuropsychiatric disorders, e.g., AD.
Keywords: histamine H3 receptor, antagonist, learning, memory impairment, passive avoidance paradigm, novel
object recognition, elevated plus maze
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INTRODUCTION
The main representative character of AD as a neurogenerative
disease and related dementias, e.g., cognitive deficit associated
with schizophrenia (CDS), is the progressive decline in
cognitive performance (Medhurst et al., 2007, 2009; Silva et al.,
2014), and enhancing cognitive functions in these conditions
embodies a multifaceted task, given the fact that various
brain neurotransmission systems and several brain regions are
involved in the progress of these conditions (Khan et al.,
2015; Shimizu et al., 2015; Sadek et al., 2016a,c). Current
pharmacological interventions for AD, such as cholinesterase
inhibitors, provide only shortly timed marginal clinical benefit
(Silva et al., 2014). Hence, the difficulties to develop satisfactory
therapies of AD and CDS are still restricted due to the
complicated pathophysiology of these diseases including several
pathways, e.g., defective β-amyloid protein metabolism and
abnormalities in central neurotransmissions for acetylcholine,
glutamate, noradrenaline, serotonin, and dopamine, and the
association of these diseases with inflammatory and/or oxidative
and hormonal pathways (Doraiswamy, 2002; Cavalli et al.,
2008; Zhou et al., 2016). Importantly, the brain histaminergic
system’s role in AD has been proposed, and a variety of
pharmaceutical agents targeting central histaminergic systems
have been developed (Bishara, 2010; Baronio et al., 2014;
Sadek and Stark, 2015; Sadek et al., 2016c). Accordingly,
H3Rs functioning as auto-receptors modulate synthesis and
release of central histamine (Sadek and Stark, 2015; Sadek
et al., 2016c). Moreover, dysregulations in a wide range
of different central neurotransmitter systems, e.g., dopamine,
serotonin, GABA, and glutamate were generally hypothesized
for the H3Rs located on neurons other than histmainergic
neural cells and functioning as hetero-receptors (Witkin and
Nelson, 2004; Sadek and Stark, 2015; Sadek et al., 2016c).
Notably, H3R antagonists/inverse agonists have been found to
exhibit a unique feature by their potential cognition-enhancing
property as indicated by numerous lines of evidence from
preclinical studies. Accordingly, several H3R antagonists/inverse
agonists have been previously found to counteract DIZ-induced
memory deficits in rodents (Witkin and Nelson, 2004; Passani
and Blandina, 2011; Sadek and Stark, 2015; Sadek et al.,
2016c) Furthermore, previous preclinical as well as clinical
experiments revealed that antagonists at N-methyl-D-aspartate
receptors (NMDARs), e.g., ketamine, promote cognitive deficits
in healthy humans and exaggerate symptomatic parameters in
patients with schizophrenia (Luby et al., 1959; Ghoneim et al.,
1985; Javitt and Zukin, 1991; Krystal et al., 1994; Malhotra
et al., 1997; Brown et al., 2013). NMDAR antagonists were,
also, found to induce behavioral deficits in rodents through
impairment of their neurocognitive functions (Large, 2007).
In addition, there are several evidences that central histamine
Abbreviations: AD, Alzheimer disease; CDS, cognitive deficits associated with
schizophrenia; DIZ, dizocilpine; DOZ, donepezil; DZP, diazepam; EPM, elevated
plus maze; H3Rs, histamine H3 receptors; LTM, long-term memory; NOR,
novel object recognition; PAP, passive avoidance paradigm; PIT, pitolisant;
PYR, pyrilamine; RAMH, R-(α)-methyl-histamine; SCO, scopolamine; STL, step-
through latency; STM, short-term memory; ZOL, zolantidine.
significantly alter cognitive deficits and that antagonists/inverse
agonists selectively targeting central histamine H3Rs may
possibly lead to therapeutic entities with potential clinical
use in cognitive symptoms, e.g., AD (Witkin and Nelson,
2004; Esbenshade et al., 2008; von Coburg et al., 2009; Sadek
and Stark, 2015; Sadek et al., 2016c). Notably, numerous
developed H3R antagonists were revealed in their effects
to decrease ketamine- and DIZ-induced cognitive deficits in
several animal models of schizophrenia (Browman et al., 2004),
signifying that these drugs may also be effective against CDS
(Witkin and Nelson, 2004; Bardgett et al., 2010; Charlier
et al., 2013; Sadek and Stark, 2015; Sadek et al., 2016c).
Moreover, previous preclinical experiments showed that several
H3R antagonists, e.g., ABT-239 and A-431404, significantly
reduced ketamine- and DIZ-induced cognitive deficits in rats
when compared to standard antipsychotics, e.g., olanzapine
and risperidone (Brown et al., 2013). Based on the high
attention level generated by these preclinical outcomes, the
central H3Rs represent an attractive target for developing
novel H3R antagonists/inverse agonists with the potential role
in neuropsychiatric multi-neurotransmitter disorders, e.g., AD
and CDS (Yokoyama et al., 1993; Yokoyama, 2001; Harada
et al., 2004; Witkin and Nelson, 2004; Uma Devi et al.,
2010; Bhowmik et al., 2012; Khan et al., 2015; Sadek and
Stark, 2015; Sadek et al., 2016a,c). Therefore, the effects of
the newly developed highly potent and selective non-imidazole
H3R antagonist/inverse agonist, E159 [1-(6-(2,3-dihydro-1H-
inden-5-yloxy)hexyl)-3-methylpiperidine], with high in vitro
selectivity toward H3Rs (Lazewska et al., 2006) (Figure 1)
has been investigated on its behavioral effects on DIZ-induced
memory deficits in PAP and NOR tasks in adult male rats.
Also and since anxiety and motor activity could confound
learning and memory’s performance of animals (Sadek et al.,
2016e), the effects of E159 on locomotor activity and anxiety-like
behaviors of the same animals in EPM were tested. Moreover,
the abrogative effects of PYR, ZOL, and SCO on the E159-
provided memory-enhancing effects in PAP and NOR tests were
assessed.
FIGURE 1 | Chemical structure and in vitro affinities of the non-imidazole H3R
antagonist/inverse agonist E159. a [125 I]Iodoproxyfan binding assay at human
H3Rstably expressed in CHO-K1 cells, n = 3 (Ligneau et al., 1994; Ligneau
et al., 2000; Lazewska et al., 2006). b [3H]Histamine binding assay performed
with cell membrane preparation of Sf9 cells transiently expressing the human
histamine H4Rand co-expressed with Gα i2 and Gβ1γ2 subunits, n = 3 (Meier
et al., 2001; Amon et al., 2007; Isensee et al., 2009; Tomasch et al., 2013).
c [3H]Pyrilamine binding assay performed with cell membrane preparation of
CHO-hH1Rcells stably expressing the human H1R, n = 3 (Schibli and
Schubiger, 2002; van Staveren and Metzler-Nolte, 2004; Schlotter et al.,
2005).
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MATERIALS AND METHODS
Animals
Inbred male Wistar rats aged 6–8 weeks (body weight: 180–220 g,
Central Animal Facility of the UAE University) were maintained
in an air-conditioned animal facility room with controlled
temperature (24◦C ± 2◦C) and humidity (55% ± 15%) under a
12-h light/dark cycle. The animals were given free access to food
and water. All experimental procedures were conducted between
9:00 and 14:00 h. The procedures used to assess effects of E159
were approved by the Institutional Animal Ethics Committee
of CMHS/UAEU(A30-13). All efforts were considered to reduce
number of animals used and their suffering. Also, all behavioral
studies were conducted by the same experimenter.
Drugs
RAMH dihydrochloride, H1R antagonist PYR, H2R antagonist
ZOL dimaleate, DOZ hydrochloride, DIZ hydrogen maleate,
and SCO hydrobromide were obtained from Sigma–Aldrich
(St. Louis, MO, United States). Chemical synthesis, analysis, and
approval of the structure for E159 [1-(6-(2,3-dihydro-1H-inden-
5-yloxy)hexyl)-3-methylpiperidine] and PIT were conducted in
the Department of Technology and Biotechnology of Drugs
(Kraków, Poland) as described previously (Lazewska et al., 2006).
DZP manufactured by Gulf Pharmaceutical Industries (Ras Al
Khaimah, United Arab Emirates) was obtained from Dr. Ameen
Al Amaydah (Department of Emergency Medicine, Emirates
International Hospital, Al Ain, United Arab Emirates). All doses
were expressed in terms of the free base of all drugs. The drugs
used in the current study were dissolved in saline and injected
i.p. at a volume of 1 ml/kg. All experimental procedures were
carried out in a blinded fashion in which the experimenter was




The step-through PAP test was done as previously described
and in an automatically operated commercial Passive Avoidance
Apparatus (step-through cage, 7550, Ugo Basile, Comerio, Italy)
(Bernaerts et al., 2004; da Silva et al., 2009; Goshadrou et al., 2013;
Khan et al., 2015; Sadek et al., 2015, 2016a,e). The experimental
procedure consisted of two trials (training and testing) separated
by a 24 h interval. Each rat in the first trial was placed in the
white compartment, facing the auto guillotine door and, after a
30-s habituation period, the door was raised automatically, and
cut-off time of 60 s was given for the animal to cross to the dark
compartment. As soon as the rat placed all four paws in the dark
module, the guillotine door was lowered and a scrambled foot-
shock of 0.4 mA (20 Hz, 8.3 ms) was delivered to the grid floor
for 3 s. Rats that failed to move within this period were excepted
from the test on the following day. Directly after receiving the
shock, the rat was removed from the dark chamber, returned to its
home-cage, and the chambers were thoroughly cleaned. For the
second and third training day, the same procedure was followed
with the only change that a 300 s cut-off latency was allowed for
the test animal to enter the dark compartment, however, without
delivery of scrambled foot-shock. Animals that failed to cross into
the dark compartment during the training, despite the practices
conducted in training sessions, were excluded from the current
study. For each experiment, 9–11 rats having the same average
of age and weight were trained on the step-through latency
(STL) test. Approximately 2–4 rats failed to show improved
performance in a cut-off time of 60 s, a time period provided
for the animals to cross to the dark compartment. In the current
experiments, a sample group of seven rats was used for each STL
experiment conducted for the PAP. In the test session, animals
were turned amnesic with SCO (2 mg/kg) or DIZ (0.1 mg/kg)
30–45 min prior to the test session, and the rats were given a
maximum of 300 s to move into the dark box. In this test session,
the STL time taken by the animal to enter the dark box or STL
in 5 min was recorded and documented. In order to identify
a procognitive effect, 11 groups were acutely pretreated with
Saline + Saline, DIZ (0.1 mg) + Saline, DIZ (0.1 mg) + E159
(2.5 mg), DIZ (0.1 mg) + E159 (5 mg), DIZ (0.1 mg) + E159
(10 mg), DIZ + DOZ (1 mg), or DIZ + PIT (10 mg) 30–45 min
prior to the test session, respectively, and their effects on DIZ-
induced memory deficits were measured by determining the STLs
to enter the dark box. The E159-provided procognitive effect
was confirmed by conducting additional experiments in which
the respective promising dose of E159 (2.5 mg/kg) and PYR
(10 mg/kg), ZOL (10 mg/kg), SCO (1 mg/kg), or a combination
of SCO and ZOL were co-injected. The doses of SCO, PYR,
and ZOL were selected according to previous studies (Orsetti
et al., 2001, 2002; Khan et al., 2015; Sadek et al., 2015, 2016a,b,d)
(Figures 2–4).
NOR Test
Novel Object Recognition was assessed with a slight modification
as previously described (Ennaceur and Delacour, 1988; Izquierdo
et al., 1999; de Lima et al., 2005; Karasawa et al., 2008). The
experiments were conducted in a black open field box measuring
50 cm × 35 cm × 50 cm. The experimental procedure included
two sessions of habituation separated with a 1-h interval, whereby
the animals were permitted for exploratory time of 3-min. On
the test day, animals were placed in the test box, and after a 3-
min of exploration, two objects (9 cm × 5 cm × 9 cm wood
blocks which were in duplicate of the same size but different
shape and color) were presented in two corners (approximately
30 cm apart from each other). The experimental session (24 h
later) consisted of two trials, namely T1 and T2, each of a
duration of 3 min. In T1, rats were exposed to two identical
objects, and rats which explored the objects for less than 10 s
during T1 were excluded from the experiments. In T2, performed
120 min for STM or 24 h for LTM later, animals were exposed
to two objects, one of which was replaced with a new object
and the other object was a duplicate of the familiar one to
exclude olfactory traits. Also, the familiar or new object as well
as the relative position of the two objects were counterbalanced
and randomly permuted during trial T2. The measurement was
obtained with the time spent by the animal exploring both
objects during T1 and T2, and exploration of an object was
defined as touching one of both objects with the nose. Other
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FIGURE 2 | Effects of E159 on DIZ-induced memory deficits in an inhibitory
avoidance conditioned response in rats. Gray columns represent the mean
STLs measured during the retention test (test latencies) and black columns
the mean STLs measured during the training trial before the delivery of the
foot-shock (pre-shock latencies). Rats were injected with E159 (2.5, 5, or
10 mg/kg, i.p.), DOZ (1 mg/kg, i.p.), or PIT (10 mg/kg, i.p.) 30–45 min before
the test session. ∗∗P < 0.001 for mean STLs vs. the value of the
(saline)-treated group. #P < 0.005 for mean STLs vs. the value of the [E159
(2.5 mg)]-treated group. $P < 0.001 for mean STLs vs. the value of the
(saline)-treated group. Data are expressed as mean ± SEM (n = 7).
behavioral observations, e.g., turning around or sitting on the
object was not considered an experimental behavior. The open
field arena as well as the objects were carefully cleaned using
70% (volume/volume; v/v) alcohol. DIZ and all test compounds
were dissolved in saline and administered i.p. 30 min following
T1 at a volume of 1 ml/kg, and the doses were expressed in
terms of the free base. The control groups received an equivalent
volume of saline. The doses chosen for the NOR test were
derived from the results in PAP and/or previously reported
procognitive studies (Bernaerts et al., 2004; da Silva et al., 2009;
Goshadrou et al., 2013; Khan et al., 2015; Sadek et al., 2015;
Sultan et al., 2017). In order to detect a procognitive effect
for STM, eight groups of 6–8 rats each were used. They were
injected with Saline + Saline, DIZ + Saline, DIZ + E159 (2.5
mg/kg), DIZ + E159 (2.5 mg) + RAMH (10 mg), DIZ + DOZ
(1 mg), DIZ + RAMH (10 mg), Saline + E159 (2.5 mg/kg), or
Saline+ RAMH (10 mg/kg) 30–45 min after T1, and their effects
on DIZ-induced cognitive deficits (STM) were measured by
determining the time spent by the rat in exploring objects during
trials T1 and T2 (Figure 4). Moreover, the variable N-F/N + F
which provides the discrimination index (D) was computed.
Also and in order to exclude any confounding factors, E159
(2.5 mg/kg) and RAMH (10 mg/kg) were tested on their effect on
two separate saline-treated control groups. The above mentioned
experimental protocol was applied to detect the procognitive
effect for LTM in another six groups of 6–8 rats each, however,
with the only change that E159 (2.5 mg/kg, i.p.) was administered
30–45 min prior to T2. They were injected with Saline + Saline,
FIGURE 3 | Effect of vehicle, E159, PYR, and ZOL on DIZ-induced deficit in
an inhibitory avoidance conditioned response in rats. Gray columns represent
the mean STLs measured during the retention test (test latencies) and black
columns the mean STLs measured during the training trial before the delivery
of the foot-shock (pre-shock latencies). Rats were injected with E159
(2.5 mg/kg, i.p.), PYR (10 mg/kg, i.p.) or ZOL (10 mg/kg, i.p.) 30–45 min
before the test session. $P < 0.001 for mean STLs vs. the value of the
(Saline)-treated group. ∗∗P < 0.001 for mean STLs vs. the value of the
(DIZ)-treated group. ∗P < 0.001 for mean STLs vs. the value of the
(DIZ + E159)-treated group. &P < 0.05 vs. the value of the (DIZ)-treated
group. Data are expressed as mean ± SEM (n = 7).
DIZ + Saline, DIZ + E159 (2.5 mg/kg), DIZ + DOZ (1 mg),
Saline+ E159 (2.5 mg/kg), or Saline+DOZ(1 mg/kg) (Figure 5).
In all experiments, doses of DIZ, RAMH, and DOZ were selected
according to previous studies (Bernaerts et al., 2004; de Lima
et al., 2005; da Silva et al., 2009; Goshadrou et al., 2013; Khan
et al., 2015; Sadek et al., 2015, 2016a; Sultan et al., 2017)
(Figures 5, 6).
EPM Test
Anxiety-like behaviors were with slight modification assessed
in an EPM as previously described (Jiang et al., 2016). The
EPM apparatus consisted of several parts including one central
part (8 cm × 8 cm), two opposing open and closed arms
(30 cm × 8 cm), and non-transparent walls (30 cm in
height). The experiment room was light and temperature-
controlled, and both the plat form and the wall were thoroughly
cleaned between every session using 10% ethanol spray.
Animals were placed individually in the center arena of the
maze (50 cm above the floor) facing the open arm. The
measurement was carried out by observing the amount of
time spent with head and forepaws on the open arms and
closed arms of the maze and the number of entries into each
arm was manually scored for a duration of 5 min. In this
experiment, the total number of entries into the closed arms
is typically considered as an index for locomotor activity of
the respective tested animal. In order to detect anxiety-like and
locomotor behavior, three groups of 8–10 animals each were
injected i.p. with saline (Saline group) and two test groups
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FIGURE 4 | Effect of vehicle, E159, ZOL, and SCO on DIZ-induced deficit in
an inhibitory avoidance conditioned response in rats. Gray columns represent
the mean STLs measured during the retention test (test latencies) and black
columns the mean STLs measured during the training trial before the delivery
of the foot-shock (pre-shock latencies). Rats were injected with E159
(2.5 mg/kg, i.p.), ZOL (10 mg/kg, i.p.), SCO (1 mg/kg, i.p.) or a combination of
ZOL (10 mg/kg) + SCO (1 mg/kg) 30–45 min before the test session.
$P < 0.001 for mean STLs vs. the value of the (Saline)-treated group.
∗∗P < 0.001 for mean STLs vs. the value of the (DIZ)-treated group.
#P < 0.05 for mean STLs vs. the value of the (DIZ + E159 + ZOL)- and
(DIZ + E159 + SCO)-treated group vs. the value of the (DIZ)-treated group.
Data are expressed as mean ± SEM (n = 7).
that received either E159 (2.5 mg/kg) or DZP (10 mg/kg)
(Figures 7A–D).
Statistical Analysis
IBM R© SPSS Statistics R© version 20 software (IBM Middle East,
Dubai, United Arab Emirates) was used for all statistical
comparisons in all behavioral experiments. Data were expressed
as means ± SEM. The effects of E159 on DIZ-induced memory
deficits were analyzed using a two-way analysis of variance
(ANOVA) with Treatment (vehicle or E159) and Dose (E159) as
the between-subjects factor. The effect of E159 in combination
with PYR, ZOL, or SCO on STL time was analyzed using
one-way ANOVA with Treatment as the between-subject factor.
The effects of E159 with the most promising dose in PAP
(2.5 mg/kg) on DIZ-induced amnesia in NOR test were analyzed
using a mixed repeated-measure two-way analysis of variance
(ANOVA) with Treatment (vehicle or E159) and Dose (E159;
2.5 mg/kg, i.p.) as the between-subjects factor. The effect of
E159 (2.5 mg/kg) in EPM test were assessed by measuring the
time spent on the open arms and closed arms of the maze
as well as the number of entries into each arm. The results
observed in EPM test were analyzed using one-way ANOVA
with Treatment as the between-subject factor. In case of a
significant main effect, post hoc comparisons were performed
with Bonferroni’s test. The criterion for statistical significance was
set at p ≤ 0.05.
FIGURE 5 | Effects of E159 on DIZ-induced STM cognitive deficits in the
object recognition test in rats. Thirty minutes following training session T1,
E159 (2.5 mg/kg), RAMH (10 mg/kg), DOZ (1 mg/kg), or DIZ (0.1 mg/kg) was
administrated intraperitoneally. The test session T2 was performed 120 min
(STM) after the training session T1. Results are calculated as individual
percentage of time spent exploring familiar (black columns) and novel (gray
columns) objects. Data represent mean ± SEM of 6–8 animals per
experimental group. ∗∗∗P < 0.001 vs. respective familiar object.
FIGURE 6 | Effects of E159 on DIZ-induced LTM cognitive deficits in the
object recognition test in rats. Thirty minutes following training session T1,
E159 (2.5 mg/kg), DOZ (1 mg/kg), or DIZ (0.1 mg/kg) was administrated
intraperitoneally. The test session T2 was performed 24 h (LTM) after the
training session T1 in which E159 (2.5 mg/kg) was administered 30–45 min
before T2. Results are calculated as individual percentage of time spent
exploring familiar (black columns) and novel (gray columns) objects. Data
represent mean ± SEM of 6–8 animals per experimental group. ∗∗∗P < 0.001
vs. respective familiar object.
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FIGURE 7 | Effects of acute E159 pretreatment on exploratory behavior in the EPM test. E159 (0 or 2.5 mg/kg) did not change the percentage of time spent on the
open arms of the EPM (A), the number of entries into the open arms (B), and the percentage of entries into the open arms (C). Pretreatment with the H3R
antagonist/inverse agonist E159 did not affect the number of closed arm entries (D). However, DZP significantly increased the percentage of time spent on the open
arms of the EPM (A), increased the number of entries into the open arms (B) and the percentage of entries into the open arms (C), without significant alteration in
the number of closed arm entries (D). Data are expressed as mean ± SEM (n = 8–10). ∗P < 0.05 for the value of DZP-treated group vs. the value of the E159
(Saline)- or (2.5 mg)-treated group.
RESULTS
Effects of E159, DOZ, and PIT on
DIZ-Induced Memory Impairment in
Step-Through PAP
Figure 2 shows the effect of E159 (2.5, 5, and 10 mg/kg),
DOZ (1 mg/kg), and PIT (10 mg/kg) on DIZ-induced memory
impairments in step-through PAP in rats. When injected before
the retention test, one-way analysis of variance showed that
acute systemic prtreatment with E159 (2.5, 5, and 10 mg/kg),
DOZ (1 mg/kg), and PIT (10 mg/kg) exihbited a significant
effect on STLs [F(13,84) = 9.691; P < 0.001]. Also and as
compared to the (saline)-treated group, subsequent post hoc
analyses showed that DIZ (0.1 mg/kg) decreased STL time
with [F(1,12) = 820.401; P < 0.001]. In addition, E159 (2.5
and 5 mg/kg), DOZ (1 mg/kg), and PIT (10 mg/kg) exerted
significant memory-enhancing effect on STLs when compared
to (DIZ)-treated group with [F(1,12) = 34.631; P < 0.001],
[F(1,12) = 15.392; P < 0.001], [F(1,12) = 95.365; P < 0.001],
and [F(1,12) = 30.074; P < 0.001], respectively. The procognitive
effects observed for E159 at a dose of 2.5 mg/kg were not
significantly different from (Saline)-treated rats (p = 0.1703).
However, E159 tested at a dose of 10 mg/kg failed to exhibit
significant memory enhancing effect when compared to (DIZ)-
treated group (p= 0.093).
Effects of PYR and ZOL on the
E159-Provided Memory Improvement in
DIZ-Induced Deficit in Step-Through PAP
For this experiment, separate groups of rats (n = 7 for
each group) were pretreated with either the CNS-penetrant
H1R antagonist PYR (10 mg/kg) or the CNS-penetrant H2R
antagonist ZOL (10 mg/kg) 30–45 min prior to the test
session. As shown in Figure 3, pairwise comparisons reported
that, as expected, acute systemic pretreatment with E159
(2.5 mg/kg, i.p.) prolonged STL time when compared to
the (DIZ)-treated group with [F(1,12) = 34.346; P < 0.001].
This E159-provided prolongation of STL time was partly
abrogated following ZOL [F(1,12) = 9.437; p = 0.009:
Saline + DIZ + E159 vs. DIZ + E159 + ZOL], but not following
an acute systemic administration with PYR when compared to
(Saline+DIZ+ E159)-treated group [F(1,12) = 2.082; p= 0.175].
Notably, neither Saline + Saline + DIZ vs. Saline + DIZ + PYR,
nor Saline + Saline + Saline vs. Saline + DIZ + ZOL differences
were found to be significant (p= 0.70 and p= 0.47, respectively)
(Figure 3).
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Effects of ZOL, SCO, and a Combination
of ZOL and SCO on the E159-Provided
Memory-Improvement in DIZ-Induced
Deficit in Step-Through PAP
As depicted in Figure 4, one-way analysis of variance showed
that acute systemic pretest administration with E159 (2.5 mg/kg),
ZOL (10 mg/kg), SCO (1 mg/kg), and combination of ZOL
(10 mg/kg) with SCO (1 mg/kg) exerted a significant memory
improving effect on STLs [F(7,48) = 29.436; P < 0.001]. Moreover,
subsequent post hoc analyses revealed that DIZ (0.1 mg/kg)
reduced STL time with [F(1,12) = 849.171; P < 0.001] when
compared to the (Saline)-treated group (Figure 4). Furthermore,
E159 (2.5 mg/kg) exhibited significant improving effect on STLs
with [F(1,12) = 34.346; P < 0.001] when compared to (DIZ)-
treated group, and this E159-induced improvement of STL
time was not completely abrogated following acute systemic
co-administration with ZOL (10 mg/kg) or SCO (1 mg/kg)
with [F(1,12) = 21.382; P < 0.001: Saline + Saline + DIZ
vs. DIZ + E159 + ZOL] and [F(1,12) = 8.429; P < 0.05:
Saline + Saline + DIZ vs. DIZ + E159 + SCO]. In addition,
an acute systemic pretreatment with ZOL (10 mg/kg) combined
with SCO (1 mg/kg) showed significantly higher abrogative effect
on the E159-provided memory improvement when compared
with the abrogation observed by ZOL or SCO administered
alone with [F(1,12) = 11.466; P < 0.05: DIZ + E159 + ZOL vs.
DIZ + E159 + ZOL + SCO] and [F(1,12) = 5.288; P < 0.05:
DIZ+ E159+ SCO vs. DIZ+ E159+ ZOL+ SCO], respectively.
Interestingly, SCO failed to alter STL time in both (Saline)-
and Saline + DIZ-treated group (p = 0.757 and p = 0.334,
respectively) (Figure 4).
Effects of E159 and DOZ on DIZ-Induced
STM Deficits in NOR
The results observed in NOR test for the total time exploring
both objects during training and test session of the respective
group revealed that there were no significant differences
between (Saline)- and DIZ-treated groups (Table 1). The latter
observation is important to exclude any confounding factors,
e.g., that the acute post-training injection with DIZ in the first
experiment did not modulate locomotor activity or motivation
as sensorimotor parameters. Also, statistical analyses of results
observed for exploratory time during T1 revealed that no
significant differences were present in exploration between
the two identical objects. Figure 5 shows the effect of E159
(2.5 mg/kg) and DOZ (1 mg/kg) on DIZ-induced STM deficits of
memory in NOR. Moreover, one-way analysis of variance showed
that acute systemic pretreatment with E159 (2.5 mg/kg) and
DOZ (1 mg/kg) exhibited a significant effect on exploratory time
spent with both objects in T2 with [F(7,40) = 5.799; P < 0.001]
when injected 30 min after training session T1. As shown by
subsequent post hoc tests, DIZ (0.1 mg/kg) decreased memory
for the novel object in T2 with [F(1,12) = 205.423; P < 0.001]
when compared to the (saline)-treated group. However, E159
(2.5 mg/kg) enhanced impaired STM when compared to (DIZ)-
treated group with [F(1,12) = 24.396; P < 0.001], and was
comparable to the DOZ(1 mg/kg)-provided memory-enhancing
effect (p = 0.706) (Figure 5). Moreover, discrimination indices
measured for the different groups in STM support the latter
observed results (Table 1).
Effects of E159 and DOZ on DIZ-Induced
LTM Deficits in NOR
One-way analysis of variance revealed that acute systemic
pretreatment with E159 (2.5 mg/kg) and DOZ (1 mg/kg) exerted
no significant effect on time spent exploring objects in T2
with [F(5,30) = 1.293; p = 0.293] when injected 30 min after
training session T1 and 60 min before T2 and 24 h later
(Figure 6). As shown by subsequent post hoc analyses, DIZ
(0.1 mg/kg) impaired memory for the novel object in T2 with
[F(1,10) = 12.788; P < 0.05] when compared to the (Saline)-
treated group (Figure 6). Moreover, acute systemic pretreatment
with DOZ (1 mg/kg) enhanced LTM with [F(1,10) = 7.485;
P < 0.05] as compared to (DIZ)-treated group. However, E159
(2.5 mg/kg) failed to significantly enhance LTM when compared
to (DIZ)-treated group with [F(1,10) = 1.094; p = 0.320]. Also,
acute systemic administration of E159 (2.5 mg/kg) or DOZ
(1 mg/kg, i.p.) alone failed to modulate LTM in T2 when
compared to the DIZ-treated group with [F(1,10) = 2.285;
p = 0.057] and [F(1,10) = 0.765; p = 0.402], respectively
(Figure 6). Also, observed discrimination indices for the
different treated groups support the latter results in LTM
(Table 1).
Effect of E159 on Rat Performance in
EPM Test
Figure 7 shows the effects of acute administration of E159 (0
or 2.5 mg/kg) on the percentage of time spent in open arms,
number of entries into open arms, percentage entries into open
arms, and locomotor activity (number of entries into closed arm)
of rats observed in the EPM test. Post hoc analyses indicated
that compared to saline, E159 failed to alter the percentage
of time spent exploring the open arms of the maze during a
5-min session with [F(1,14) = 0.001, p = 0.981] as compared
to the (Saline)-treated group (Figure 7A). Moreover, statistical
analyses of data describing the number and percentage of entries
into the open arms of the maze [F(1,12) = 1.389, p = 0.261;
F(1,10) = 0.003, p = 0.954, respectively) generated essentially
the same results. As shown in Figures 7B,C, no significant
difference from that obtained with the (Saline)-treated group
were observed following acute systemic administration with
E159 (2.5 mg/kg). However, the percentage time spent in open
arms and number and percentage of entries into open arms
were significantly modulated after acute systemic administration
of DZP (10 mg/kg, i.p.) with [F(1,12) = 14.482, P < 0.05],
[F(1,10) = 13.257, P < 0.05], and [F(1,11) = 15.805, P < 0.05],
respectively (Figures 7A–C). Interestingly, the number of closed
arm entries following E159 (2.5 mg/kg) or DZP (10 mg/kg)
injections with [F(1,14) = 0.554, p = 0.469] and [F(1,12) = 1.311,
p = 0.275] were not significantly changed, indicating that
locomotor activity per se was not modulated subsequent to
acute administrations of E159 or DZP when compared to
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TABLE 1 | Effects of E159 on DIZ-induced total amount of time spent exploring both objects during object recognition training and test session in rats.
Time exploring objects (s) Discrimination index “D”a
Group n STM T1 STM T2 LTM T1 LTM T2 STM LTM
Saline 6 37.50 ± 3.20 37.83 ± 3.39 36.67 ± 2.95 39.83 ± 3.22 0.51 ± 0.05 0.36 ± 0.04
DIZ (0.1 mg/kg) 8 36.00 ± 2.73 42.25 ± 1.57 23.33 ± 2.01 22.67 ± 2.35 0.03 ± 0.01∗ 0.03 ± 0.07∗
DIZ + E159 (2.5 mg/kg) 8 23.75 ± 2.18 22.67 ± 4.84 24.63 ± 2.74 27.67 ± 3.48 0.14 ± 0.05# 0.05 ± 0.09
DIZ + E159 (2.5 mg/kg) + RAMH (10 mg/kg) 6 37.50 ± 1.52 41.17 ± 2.43 ND ND 0.06 ± 0.11 ND
DIZ + DOZ (1 mg/kg) 6 24.83 ± 1.72 25.33 ± 1.68 23.00 ± 3.34 21.00 ± 2.49 0.28 ± 0.11∗ 0.32 ± 0.07∗
DIZ + RAMH (10 mg/kg) 6 23.50 ± 1.41 24.33 ± 1.59 ND ND 0 ± 0.02 ND
Saline + E159 (2.5 mg/kg) 6 35.67 ± 2.93 37.33 ± 2.19 35.50 ± 2.78 36.83 ± 1.46 0.36 ± 0.07 0.24 ± 0.15
Saline + RAMH (10 mg/kg) 6 35.67 ± 2.93 32.33 ± 1.59 ND ND 0.34 ± 0.09 ND
Data are expressed as mean ± SEM of 6–10 animals per experimental group. There were no significant differences among training and test exploring time in STM and
LTM group of each respective treatment.
aDiscrimination index (D) calculated as; D = N − F/N + F, where N and F are the time spent with novel object and familiar object, respectively. ND, not determined.
∗P < 0.05 for mean D vs. the value of the (DIZ)-treated group vs. value of (Saline)-treated group. #P < 0.05 for mean D vs. the value of the (Saline)- and (DIZ+ E159)-treated
group vs. the value of the (DIZ)-treated group. Data are expressed as mean ± SEM (n = 7).
that obtained with saline pretreatment (Figure 7D). Therefore,
the detected behavioral alterations were not influenced by any
substantial modifications in the traveled distance during the test
period.
DISCUSSION
Mounting evidences show that acute systemic administration
of NMDAR antagonists such as DIZ (Luby et al., 1959)
reduces performance of experimental rodents in a wide-
ranging varieties of learning and memory tasks (Javitt and
Zukin, 1991) including PAP and NOR (Luby et al., 1959;
Ghoneim et al., 1985; Javitt and Zukin, 1991; Krystal et al.,
1994; Malhotra et al., 1997; Brown et al., 2013; Khan et al.,
2015; Sadek and Stark, 2015; Sadek et al., 2016a,c). Therefore,
DIZ-induced dementia has been commonly used to evaluate
potential therapeutic agents for treating AD and CDS (Luby
et al., 1959; Ghoneim et al., 1985; Javitt and Zukin, 1991;
Krystal et al., 1994; Malhotra et al., 1997; Brown et al.,
2013). In this study, acute systemic administration of E159
only at lower doses (2.5 and 5 mg/kg) significantly reversed
the DIZ-induced memory deficits in PAP test in adult rats
(Figure 2). It has been proposed that NMDA receptors
participate with a significant function in several stages of
memory, namely consolidation and retrieval processes (Vorobjev
et al., 1993; Brabant et al., 2009, 2013). Therefore, it is
possible that in our experiments E159 moderately reduced DIZ-
induced memory deficits through direct stimulation of NMDA
receptors by the increased release of central histamine as a
consequence of blocking histamine H3 auto-receptors by this
class of H3R antagonists. These results are in consensus with
earlier observations in which histamine was found to improve
transmission in cultured hippocampal cells mediated by NMDA
receptors, indicating that the interaction between histamine and
NMDA receptors possibly will enable the histamine’s capability
reduce DIZ-induced memory deficits (Vorobjev et al., 1993;
Xu et al., 2005; Brabant et al., 2013; Sadek et al., 2016a).
Importantly, the memory-enhancing effect observed for E159
was dose-dependent, since the improvement of memory provided
by E159 (2.5 mg/kg) in the DIZ-induced amnesia model
was significantly higher when compared to the higher doses
(5 and 10 mg/kg), demonstrating that an optimum in memory-
enhancing effect was observed when the H3R antagonist/inverse
agonist E159 was applied at the lowest dose (2.5 mg/kg),
and an off-target effect for E159 at higher doses (5 and
10 mg/kg) might have been observed in the current study
(Figure 2). The latter observations of dose dependency are,
also, in agreement with earlier experimental results conducted
in different rodents (Benetti and Izquierdo, 2013; Benetti et al.,
2013; Sadek et al., 2015). Moreover, the observed cognitive
enhancing effects for E159 (2.5 mg/kg) were similar to those
obtained for the reference H3R antagonist/inverse agonist PIT
and the reference drug DOZ (Figure 2). Furthermore, the
E159 (2.5 mg/kg)-provided memory-enhancing effects were
moderately reversed when rats were administered with the CNS-
penetrant H2R antagonist ZOL but not with the CNS-penetrant
H1R antagonist PYR. The latter observation confirmed our
previous results observed for the non-imidazole H3R antagonist
DL77 (2.5–10 mg/kg) in different memory processes, namely
acquisition, consolidation, and retrieval (Sadek et al., 2016e).
The ameliorative effects found for E159 in DIZ-induced memory
deficits further indicate that histaminergic pathways through
activation of H2Rs are fundamentally contributing in neuronal
pathways important for alteration of retrieval processes. An
additional experiment revealed that the E159-provided memory-
enhancing effect was, also, moderately abrogated when animals
were administered with SCO, however, significantly further
abrogated when animals were administered with a combination
of SCO and ZOL (Figure 3). The latter experimental finding
clearly indicates that cholinergic muscarinic neurotransmission
as well as histaminergic circuits through activation of H2Rs
are strongly involved in the E159-provided memory enhancing
effects (Figure 3). Unlike the PAP test, NOR test in rodents
measures natural behavior of rodents and advantages from
their distinctive curiosity for discovering their surroundings,
and it does not comprise a punishment or a reward.
Frontiers in Pharmacology | www.frontiersin.org 8 October 2017 | Volume 8 | Article 709
fphar-08-00709 October 10, 2017 Time: 15:44 # 9
Alachkar et al E159 Ameliorates Memory Deficits
Notably, the NOR is a paradigm used in rodent models
to capture characteristics of the neurodevelopmental basis of
CDS by interpreting the results without confounding factors,
e.g., side effects such as antinociceptive effect of several old-
generation imidazole-based H3R antagonists/inverse agonists,
e.g., thioperamide (Jaaro-Peled, 2009; Tseng et al., 2009; Brown
et al., 2013), and it was found to show high sensitivity
to both cognition impairing (Ennaceur and Delacour, 1988;
Ennaceur and Meliani, 1992a,b) and enhancing agents (Lebrun
et al., 2000; Barak and Weiner, 2011). The results observed in
the current study showed that acute systemic post-training
administration of E159 (2.5 mg/kg) significantly improved
the time spent to explore the novel object compared with
the familiar object, and delivered a type of STM (Figure 5).
These results are in line with earlier observations which
revealed that numerous imidazole-based H3R antagonists, e.g.,
thioperamide and clobenpropit (Giovannini et al., 1999), and
non-imidazole based H3R antagonists, e.g., PIT (Ligneau et al.,
2007); GSK189254 (Giannoni et al., 2010), SAR110894 (Griebel
et al., 2012), and ABT-239 (Provensi et al., 2016) ameliorate the
amnesic effects of SCO, DIZ or time in rodents in NOR tests.
Interestingly, the STM-enhancing effects provided with E159
in DIZ-induced memory deficits were significantly abrogated
after animals were co-injected with the CNS-penetrant H3R
agonist RAMH (Figure 5). The latter observations are in line
with an earlier preclinical study in which RAMH abolished
the memory-enhancing effects obtained by the imidazole-based
H3R antagonist ciproxifan on STM in mice (Pascoli et al.,
2009). Contrary, acute systemic post-training administration
of E159 (2.5 mg/kg) failed to increase the time spent
exploring the novel objects when compared with the familiar
objects in LTM (Figure 6). These results in NOR obviously
indicate that histaminergic H3Rs are profoundly contributing
in neuronal circuits involved in the E159-provided STM-
memory enhancing effects, but not in LTM-enhancing effects
(Figure 6). Moreover, the discrepancies observed for E159 in
PAP and NOR might be explained with the differences of
conducts and measured features of both models in rodents.
Accordingly, NOR measures natural behavior of animals and
advantages from their distinctive curiosity for discovering
their surroundings, and it does not comprise a punishment
or a reward. Also, NOR is a commonly used paradigm
in rodents capture characteristics of the neurodevelopmental
basis of CDS (Jaaro-Peled, 2009; Tseng et al., 2009; Brown
et al., 2013). Interestingly, several H3R antagonists were in
previous preclinical studies identified as promising targets
for CDS and were proposed to be of potential therapeutic
value based on the fact that H3R functions as auto- and
hetero-receptor, thus, modulating the biosynthesis and release
of several neurotransmitters, including histamine, dopamine,
and acetylcholine, which are important for cognitive functions
(Brioni et al., 2011; Sadek and Stark, 2015; Sadek et al.,
2016c). Notably, E159 at the dose of 2.5 mg/kg, the dose
that provided the most promising procognitive effect in PAP
and NOR, failed to change anxiety levels and locomotor
activity of the tested rodents (Figures 7A–D). Moreover, E159
used at the same dose did not alter the number of closed
arm entries, indicating that E159 did not change locomotor
activity of rodents (Figure 7D). The latter observations are
significant, since improved performance in PAP or NOR
can be the consequence of several variables not related to
memory-enhancing effects such as modifications in emotional
responding or in spontaneous locomotor activity (McGaugh
and Roozendaal, 2009; Charlier et al., 2013). These results
are, also, in agreement with previous observations in which
acute systemic administration of the H3R antagonist DL77
(2.5–10 mg/kg) failed to modify spontaneous locomotor activity
of the same animal species in the open field test (Sadek et al.,
2016e).
CONCLUSION
The observed results show that the non-imidazole H3R
antagonist E159 reduces DIZ-induced cognitive deficits in
PAP and NOR task in adult male rats. Also, the results
observed in PAP reveals that acute systemic pretreatment
with E159 in DIZ-induced amnesia models significantly
ameliorates cognitive impairments via mechanisms dependent
on cholinergic muscarinic neurotransmission and – at
least partially – H2Rs activation. Moreover, the present
results strongly support the potential therapeutic value of
histamine H3R antagonists in the treatment of neuropsychiatric
diseases, e.g., AD and CDS. Nonetheless, additional preclinical
experiments are still warranted with a series of further
behavioral test models and with different rodent species to
increase the validity of the translational value for possible
applicability of H3R antagonists/inverse agonists in the
modulation of memory impairment in several neuropsychiatric
diseases.
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